Intellicyt iQue3 – Faster, Smarter Flow Cytometry
This advanced flow cytometry platform is a complete instrument, reagents and software solution streamlined to rapidly generate results not just data.
List view / Grid view
This advanced flow cytometry platform is a complete instrument, reagents and software solution streamlined to rapidly generate results not just data.
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
Sartorius Cubis® II is designed to follow US FDA data integrity principles that require data to be accurate, legible, contemporaneous, original and attributable.
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
Ensure reproducibility with TruBIOME™ - the unique approach to generating research model colonies, which allows you complete control over their microbiome, from conception to cohort delivery.
High-content analysis app note: Phenotypic fingerprint of cellular function following gene editing by high-throughput imaging acquisition and analysis.
High-content analysis: monitoring neurite morphology and synapse formation in primary neurons for neurotoxicity assessments and drug screening.
Dr Kaylene Simpson, Peter MacCallum Cancer Center, describes their research using high content imaging to examine RNA in cancer cells.
Michael Johnson and his team at Visikol talk about the work they do as a contract research organization on 3D Cell Cultures and how they utilize High-Content Analysis / Screening to generate insights.
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.